| Symbol | ROTH |
|---|---|
| Name | PHARMAROTH LABS, INC. |
| Sector | UNDEFINED |
| Region | North America |
| Industry | - |
| Address | 89144 United States NV 10325 Falls Church Ave. |
| Telephone | 7027786795 |
| Fax | — |
| — | |
| Website | http://www.pharmaroth.com |
| Incorporation | US |
| Incorporated On | 2000 |
| Employees | — |
| Fiscal Year | 6/30 |
| Public Since | — |
| Exchanges | OTC |
| Auditor | Carlaris LV Inc.; |
| Audit Status | UNAUDITED |
| Reporting Status | Dark: Alternative Reporting Standard |
| CIK | 0001409475 |
| Description | PharmaRoth Labs, Inc. is focused on diabetes prevention and treatments. The Company holds the intellectual property and all exclusive world-wide rights related to the production, marketing, and distribution of Sucanon(R), an oral treatment for Type-II diabetes. Sucanon(R) is a member of a class of diabetic medications called insulin sensitizers. Insulin sensitizers lower blood sugar by increasing the muscle, fat and livers sensitivity to insulin. Insulin sensitizers are blood sugar normalizing or euglycemic drugs that help return the blood sugar to the normal range without the risk of low blood sugars. PharmaRoths strategy is to increase awareness, acceptance, and distribution of Sucanon(R) globally. Additional info from OTC: |
Expert Market symbol attribute type Security_Name was changed. Previous value: -. New value: PHARMAROTH LABS INC.
Read moreOTCQX U.S. Premier symbol attribute type Security_Name was changed. Previous value: CONSUMERS BANCORP INC. New value: PHARMAROTH LABS INC.
Read more